Related references
Note: Only part of the references are listed.Intravenous acetaminophen (at 15 mg/kg/dose every 6 hours) in critically ill preterm neonates with patent ductus arteriosus: A prospective study
Kannan Sridharan et al.
JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS (2021)
Fatal liver failure after therapeutic doses of paracetamol in a patient with Duchenne muscular dystrophy and atypical pharmacogenetic profile of drug-metabolizing enzymes
Yvonne Elisabeth Lao et al.
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY (2020)
Efficacy and Safety of Paracetamol for Patent Ductus Arteriosus Closure in Preterm Infants: An Updated Systematic Review and Meta-Analysis
Yingqi Xiao et al.
FRONTIERS IN PEDIATRICS (2020)
Ontogeny of Hepatic Sulfotransferases and Prediction of Age-Dependent Fractional Contribution of Sulfation in Acetaminophen Metabolism
Mayur K. Ladumor et al.
DRUG METABOLISM AND DISPOSITION (2019)
Cytochrome P450 3A4, 3A5, and 2C8 expression in breast, prostate, lung, endometrial, and ovarian tumors: relevance for resistance to taxanes
Maarten van Eijk et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2019)
Are some people at increased risk of paracetamol-induced liver injury? A critical review of the literature
Thomas M. Caparrotta et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2018)
Exposure to acetaminophen and all its metabolites upon 10, 15, and 20mg/kg intravenous acetaminophen in very-preterm infants
Robert B. Flint et al.
PEDIATRIC RESEARCH (2017)
Genetic polymorphisms of cytochrome P450-1A2 (CYP1A2) among Emiratis
Mohammad M. Al-Ahmad et al.
PLOS ONE (2017)
Preterm birth: Case definition & guidelines for data collection, analysis, and presentation of immunisation safety
Julie-Anne Quinn et al.
VACCINE (2016)
Clinical Pharmacology of Paracetamol in Neonates: A Review
Gian Maria Pacifici et al.
CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL (2015)
Developmental changes rather than repeated administration drive paracetamol glucuronidation in neonates and infants
Elke H. J. Krekels et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2015)
PharmGKB summary: pathways of acetaminophen metabolism at the therapeutic versus toxic doses
Liudmila L. Mazaleuskaya et al.
PHARMACOGENETICS AND GENOMICS (2015)
Pharmacogenomic implications of population admixture: Brazil as a model case
Guilherme Suarez-Kurtz et al.
PHARMACOGENOMICS (2014)
Pharmacogenomics of acetaminophen in pediatric populations: a moving target
Anne E. Krasniak et al.
FRONTIERS IN GENETICS (2014)
Candidate Gene Polymorphisms in Patients with Acetaminophen-Induced Acute Liver Failure
Michael H. Court et al.
DRUG METABOLISM AND DISPOSITION (2014)
CYP3A4*1B polymorphism and cancer risk: A HuGE review and meta-analysis
Li-Ping Zhou et al.
TUMOR BIOLOGY (2013)
Impact of CYP2D6 polymorphisms in tamoxifen adjuvant breast cancer treatment
T. Ramon y Cajal et al.
BREAST CANCER RESEARCH AND TREATMENT (2010)
Three Patterns of Cytochrome P450 Gene Expression during Liver Maturation in Mice
Steven N. Hart et al.
DRUG METABOLISM AND DISPOSITION (2009)
Sex Differences of Drug-metabolizing Enzyme: Female Predominant Expression of Human and Mouse Cytochrome P450 3A Isoforms
Tsutomu Sakuma et al.
JOURNAL OF HEALTH SCIENCE (2009)
Acetaminophen bioactivation by human cytochrome P450 enzymes and animal microsomes
J. E. Laine et al.
XENOBIOTICA (2009)
Variation in CYP1A2 activity and its clinical implications: influence of environmental factors and genetic polymorphisms
Arzu Gunes et al.
PHARMACOGENOMICS (2008)
The ontogeny of drug metabolism enzymes and implications for adverse drug events
Ronald N. Hines
PHARMACOLOGY & THERAPEUTICS (2008)
Genotype and allele frequencies of polymorphic CYP2E1 in the Turkish population
Gulen Ulusoy et al.
ARCHIVES OF TOXICOLOGY (2007)
A new CYP3A5 variant, CYP3A5*11, is shown to be defective in nifedipine metabolism in a recombinant cDNA expression system
Su-Jun Lee et al.
DRUG METABOLISM AND DISPOSITION (2007)
Pharmacogenetics, drug-metabolizing enzymes, and clinical practice
Sharon J. Gardiner et al.
PHARMACOLOGICAL REVIEWS (2006)
Symptomatic treatment of migraine in children: A systematic review of medication trials
L Damen et al.
PEDIATRICS (2005)
Functionally defective or altered CYP3A4 and CYP3A5 single nucleotide polymorphisms and their detection with genotyping tests
SJ Lee et al.
PHARMACOGENOMICS (2005)
CYP3A4 polymorphisms -: Potential risk factors for breast and prostate cancer:: A HuGE review
C Keshava et al.
AMERICAN JOURNAL OF EPIDEMIOLOGY (2004)
Genetic polymorphism of CYP1A2 in ethiopians affecting induction and expression: Characterization of novel haplotypes with single-nucleotide polymorphisms in intron 1
E Aklillu et al.
MOLECULAR PHARMACOLOGY (2003)
Polymorphisms in the cytochrome P450 CYP1A2 gene (CYP1A2) in colorectal cancer patients and controls: allele frequencies, linkage disequilibrium and influence on caffeine metabolism
C Sachse et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2003)
Genetic contribution to variable human CYP3A-mediated metabolism
JK Lamba et al.
ADVANCED DRUG DELIVERY REVIEWS (2002)
The genetic determinants of the CYP3A5 polymorphism
E Hustert et al.
PHARMACOGENETICS (2001)
Share Paper
